Plain-English translation of NCT06648434 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new medication, when combined with a standard chemotherapy regimen called for patients with metastatic pancreatic cancer (cancer that has spread beyond the pancreas). Researchers believe that may help the chemotherapy work better by blocking a protein called MK2 that helps cancer cells survive. The trial has two phases: first, doctors will find the right dose of the medication, and then they will test that dose in more patients.
Metastatic pancreatic cancer is difficult to treat and patients need better options. This medication is designed to make the standard chemotherapy more effective, potentially improving how long patients live and how well they respond to treatment.
You likely qualify if…
You likely don't qualify if…
You will take the new medication by mouth once or twice daily (depending on your assigned dose) combined with intravenous chemotherapy given on day 1 of each 2-week cycle. The chemotherapy involves several drugs given through an IV, with one drug delivered continuously over 46 hours. You will have regular clinic visits for blood work, imaging scans, and health checks to monitor how well the treatment is working and manage any side effects. The trial involves about 51 patients total across two phases.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Washington University School of Medicine
Collaborators
National Cancer Institute (NCI), Aclaris Therapeutics, Inc.
Enrollment target
~51 participants
Started
June 2025
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Moh'd Khushman, M.D.
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.